NCT00433264

Brief Summary

Despite major advances in the treatment of chronic kidney disease, the age and sex matched mortality far exceeds that of the normal population. As in the normal population, the majority of deaths are related to cardiovascular disease. Mounting data point to the lethal synergy between chronic kidney disease and cardiovascular disease. This relation is present from early stages of chronic kidney disease on. Several uremic toxins have been demonstrated to play an important role in kidney disease related endothelial dysfunction. In peritoneal dialysis patients, data on the relation between uremic toxins, endothelial dysfunction and microparticles are lacking. The investigators hypothesize that endothelial dysfunction and uremic toxins are interrelated in peritoneal dialysis patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
62

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

February 7, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 9, 2007

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

March 5, 2009

Status Verified

March 1, 2009

Enrollment Period

1.8 years

First QC Date

February 7, 2007

Last Update Submit

March 4, 2009

Conditions

Chronic Kidney Disease

Keywords

peritoneal dialysisendotheliumendothelial dysfunction

Interventions

peritoneal dialysisPROCEDURE

individualised

Also known as: individualised

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Tertiary referral center university hospital

You may qualify if:

  • age \> 18
  • Maintenance peritoneal dialysis

You may not qualify if:

  • No informed consent
  • Peritonitis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universitaire Ziekenhuizen Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum, plasma, DNA

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Interventions

Peritoneal Dialysis

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Renal DialysisRenal Replacement TherapyTherapeuticsSorption Detoxification

Study Officials

  • Bjorn Meijers, MD

    UZ Leuven

    PRINCIPAL INVESTIGATOR

  • Kathleen Claes, MD

    UZ Leuven

    PRINCIPAL INVESTIGATOR

  • Pieter Evenepoel, MD, PhD

    UZ Leuven

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

February 7, 2007

First Posted

February 9, 2007

Study Start

February 1, 2007

Primary Completion

December 1, 2008

Study Completion

December 1, 2008

Last Updated

March 5, 2009

Record last verified: 2009-03

Locations

BE(1)